Posts Tagged ‘prostate cancer’

PSA Screening: Discourage or Recommend?

Posted by • October 27th, 2011

The U.S. Preventive Services Task Force issued a draft recommendation earlier this month that men with no symptoms of prostate cancer should not be screened with the PSA test.  There has been debate about PSA screening for as long as it has existed, and that continues today.  On NEJM.org we have published the views of… Read More…

Androgen Deprivation for Prostate Cancer

Posted by • July 15th, 2011

In a new study by Jones et al., Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer, a course of androgen-deprivation therapy before and during radiotherapy prolonged 10-year survival by about 7% among men with intermediate-risk prostate cancer. The risk of erectile dysfunction with the addition of hormone therapy was also about 7% higher. In the… Read More…

An effective hormonal treatment for castration-resistant prostate cancer?

Posted by • May 25th, 2011

Prostate cancer is a hormonally driven illness that, for 70 years, has been treated in kind—by blocking androgen production or wasting its supplies. But once metastatic prostate cancer resisted the depleting effect of castration or the castrating chemotherapy agents, it was commonly believed the disease had escaped androgen regulation and hormonal agents would no longer… Read More…

Effect of Dutasteride on the Risk of Prostate Cancer

Posted by • April 2nd, 2010

Andriole et al. tested dutasteride, an inhibitor of 5-reductase in the prostate,  in a large, randomized trial to determine its ability to prevent prostate cancer. Over the 4 years of the trial, dutasteride, as compared with placebo, reduced the relative risk of biopsy-detected prostate cancer by 23%. The reduction was limited mainly to tumors with… Read More…